Peer-reviewed veterinary case report
Stem cell transplant treatment for dogs with T-cell lymphoma
By Warry, E E et al.·Published in Journal of veterinary internal medicine·2014·Department of Clinical Sciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Autologous peripheral blood hematopoietic cell transplantation in dogs with T-cell lymphoma.
- Species:
- dog
Plain-English summary
A group of 15 dogs diagnosed with high-grade T-cell lymphoma underwent a special treatment called peripheral blood hematopoietic cell transplantation (PBHCT) after receiving chemotherapy. Most of the dogs (87%) successfully recovered and showed signs of improvement, with some living for over two years after the procedure. However, two dogs did not survive the hospital stay, and one developed a different type of lymphoma later on. Overall, PBHCT could be a promising option for treating dogs with this type of cancer.
People also search for: dog T-cell lymphoma treatment · PBHCT for dogs · dog cancer survival rates · lymphoma in dogs prognosis · chemotherapy side effects in dogs
Abstract
BACKGROUND: Peripheral blood hematopoietic cell transplantation (PBHCT) is a feasible treatment option for dogs with B-cell lymphoma. OBJECTIVE: To examine apheresis and PBHCT outcomes in dogs diagnosed with T-cell lymphoma (TCL). ANIMALS: Fifteen client-owned dogs diagnosed with high-grade TCL. METHODS: After high-dose cyclophosphamide and rhG-colony-stimulating (rhG-CSF) factor treatment, peripheral blood mononuclear cells were collected using cell separators. The harvested cells then were infused after varying doses of total body irradiation (TBI). Postirradiation adverse effects were managed symptomatically and dogs were discharged upon evidence of hematopoietic engraftment. RESULTS: More than 2 × 10(6) CD34+ cells/kg were harvested from 15/15 dogs. Thirteen of 15 (87%) dogs engrafted appropriately, whereas 2 (13%) of the dogs died in the hospital. One dog developed cutaneous B-cell lymphoma 120 days post-PBHCT. The median disease-free interval and overall survival (OS) of the 13 dogs transplanted in first remission from the time of PBHCT were 184 and 240 days, respectively. Stage and substage of disease at diagnosis had no effect on OS. Two of 13 (15%) dogs were alive 741 and 772 days post-PBHCT. CONCLUSIONS AND CLINICAL IMPORTANCE: PBHCT may be considered as a treatment option for dogs with TCL.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24467413/